The World Health Organization (WHO) is developing a guideline on the prevention, diagnosis and management of delirium in older adults, including medication safety and deprescribing.
WHO is publishing the proposed membership of the Guideline Development Group (GDG) that will support the development of this guideline. The GDG will bring together experts from different disciplines and WHO regions to review and interpret the available evidence and contribute to the formulation of recommendations.
In line with WHO procedures for managing conflicts of interest, members of the public and interested organizations are invited to review the biographies of the proposed GDG members and inform WHO of any relevant information or concerns regarding an individual member’s participation in the GDG. This public consultation complements WHO’s internal review of the Declarations of Interests submitted by the proposed members.
Comments should be submitted to Matteo Cesari (mcesari@who.int) by 26 November 2026, 11:59 pm Geneva Time.
Comments should include the name, affiliation, country of residence and contact details of the person submitting them, together with the name of the proposed GDG member concerned and sufficient factual information or supporting documentation to allow WHO to assess the matter. Anonymous comments or comments that do not provide sufficient factual information may not be considered. Information received will be reviewed by the WHO Secretariat and considered, where relevant, in accordance with WHO procedures before the GDG membership is finalized.
About the Guideline Development Group
The GDG is an external group of experts that will provide scientific and technical advice to WHO throughout the guideline development process.
The Group will have two co-chairs, and will be supported by a methodologist, an evidence secretariat, and the WHO Guideline Steering Group. Members will participate in their individual capacity and not as representatives of the institutions or organizations with which they are affiliated.
The GDG will review the evidence relevant to the questions addressed by the guideline and contribute to the formulation of recommendations, taking into account the certainty of the evidence, benefits and harms, values and preferences, equity, acceptability, feasibility and resource considerations.